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Abstract
Background: Gaucher disease (GD) is due to deficiency of the glucocerebrosidase enzyme. It is panethnic, but its
presentation reveals ethnicity-specific characteristics.
Methods: We evaluated the distribution, and clinical and genetic characteristics of GD patients in the Iberian
Peninsula (IP). We analysed geographical distribution, demographic, genetic and clinical data, age at diagnosis,
type, and years of therapy in 436 GD patients from the IP.
Results: The prevalence of GD was 1/149,000 inhabitants; 88.3% were type 1, 6.7% type 2, and 5.0% type 3. The
mean age at diagnosis in type 1 was 28.7 years. A total of 72.7% were classified as having mild forms, 25.5%
moderate, and 1.7% severe. Anemia and thrombocytopenia were present in 56% and 55%, respectively. Bone
disease and hepatomegaly were reported in 62% and 68%, respectively, and were more likely in asplenic than in
non-splenectomized patients. Sixty-nine mutant alleles were identified, and five mutations accounted for 75% of
the GBA alleles. Several patients described in our series had interesting phenotypes. A total of 58.7% of patients
had received enzyme replacement therapy and 12.6% were treated with miglustat.
Conclusions: A broad spectrum of GBA mutations is present in the IP, with 98.2% of type 1 GD being mild and
23.0% never treated. These data highlight genetic and phenotypic heterogeneities among geographic populations.
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Background
Gaucher disease (GD), one of the most prevalent lysoso-
mal storage diseases worldwide, is inherited in an auto-
somal recessive mode and is usually caused by deficient
activity of the glucocerebrosidase enzyme (EC 3.2.1.45)
[1]. The predominant clinical manifestations of the dis-
ease are cytopenias, hepatosplenomegaly and bone dis-
ease. Patients with GD are divided into three types,
based on the presence and rate of progression of neuro-
logic manifestations: type 1 non-neuronopathic (MIM
230800), type 2 acute neuronopathic (MIM 230900),
and type 3 subacute neuronopathic (MIM 231000). The
type 1 form is the most common among Caucasian
patients but has a strong presence in the Ashkenazi Jew-
ish population. In contrast, there is a high frequency of
type 3 in Norrbotten, Northern Sweden, in Norrbotten
[2]. Most Chinese GD patients have an early age of
onset, severe hematological and skeletal complications,
and frequent neurological involvement, resulting in early
childhood death [3].
The human glucocerebrosidase gene (GBA) is located
on chromosome 1q21 and consists of 10 introns and 11
exons. A highly homologous GBA pseudogene lies 16 kb
downstream from the functional gene [4]. More than
300 mutations, including point mutations, deletions,
insertions, splicing aberrations and various rearrange-
ments, have been described in the GBA gene region as
the cause of GD (http://www.hgmd.org; April 2011). A
huge variation in the distribution of mutations has
nevertheless been observed in different populations. The
gene mutations have been divided into three groups
according to their phenotypic effect: null, severe, and
mild [1]. Patients carrying at least one mild mutation
have non-neuronopathic disease (GD type 1), while
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null mutation usually develop neurological symptoms
(GD types 2 and 3). For instance, it has traditionally
been considered that the N370S allele is not associated
with neuronopathic disease and that the presence of one
copy of this allele is associated with type 1 GD. How-
ever, several recent reports have described some neuro-
logical manifestations in compound heterozygous
individuals when one mutation is N370S [5]. In contrast,
homozygosity for L444P indicates that the patient is at
risk of severe disease, and fetuses with two null alleles
are non-viable [6,7]. Despite these observations, geno-
type-phenotype correlation provides guidance, but is not
an absolute predictor of outcome [8].
The N370S mutation has not been found in Japanese
patients, in contrast to the L444P mutation, which is the
most common mutation in this ethnic group [9].
Although four mutated GBA alleles (N370S, L444P,
c.84insG, and IVS2 + 1 g > a) account for most reported
cases in the Ashkenazi Jewish population, a broad spec-
trum of mutations in the GBA gene cause GD in Cauca-
sian patients [6].
The current Iberian Peninsula (IP) genetic pool has
been influenced by many major populations and immi-
grations, including the Paleolithic Iberian population,
which already existed by 50,000 B.C.E. Later immigrants
came from North Africa, entering the Iberian region
between 20,000 and 8,000 B.C.E, and the Sahara, arriv-
ing between 8,000 and 4,000 B.C.E. In addition, people
arrived from central Europe (also generically called the
Celtic invasions) during the first millennium B.C.E. At
the beginning of the eighth century, Islamic peoples
(generically called Arabs) entered Spain [10,11]. Taking
into account all these data, it is believed that the timing
of population divergence within the Iberian Peninsula
points to a shared ancestry of all populations of the
Upper Paleolithic. Further genetic subdivision is appar-
ent in Catalonia and Andalusia, with increased genetic
diversity in the latter. Lineage diversity comparisons
among IP populations, European (Tuscan) and North
African (Algerian) populations show that the IP is more
similar to other European populations, although a small
number of Iberian lineages can be traced to North
Africa.
Since the early 1970s, the groups of Dr. Chabás in
Barcelona (Spain) and Dr. Sa Miranda in Porto (Portu-
gal) have focused on the identification and study of lyso-
somal storage diseases, including GD [12-14]. Moreover,
since 1993, the Spanish Foundation for the Study and
Treatment of Gaucher Disease (FEETEG) has kept the
Spanish Registry of GD (SRGD) and also coordinates
the screening, diagnosis, characterization, treatment, and
follow-up of GD patients in Spain [15,16]. To gain
greater depth of knowledge about GD and especially its
clinical presentation, genotype distribution and geno-
type-phenotype associations, we report here the molecu-
lar characterization and associated phenotypes of a
series of 436 GD patients diagnosed in the IP.
Methods
Data collection
The dataset for this analysis included all GD patients
registered in Portugal and Spain. Data were gathered
from the National Spanish Gaucher Disease Registry
(since 1993), the Institut de Bioquímica Clínica, Hospital
Clínic and the Genetic Department of Barcelona (in the
period 1976-2002), and the Portuguese Coordinating
Committee for the Treatment of Lysosomal Storage Dis-
eases group (in the period 1993-2005). Demographic
and clinical data were collected from all the referred GD
patients during clinic visits. In addition, a clinical eva-
luation was provided by the patient’sp h y s i c i a n ,a n d
patients gave information about ethnic background. The
following baseline demographic characteristics were
recorded for each patient in the study: age, sex, ethnicity
(provided by the patients), GBA genotype, country of
origin, and status (alive/dead). Clinical characteristics of
GD at diagnosis included: age at diagnosis; organome-
galy; spleen status; cytopenias; hemoglobin, ferritin, and
gammaglobulin levels; Severity Score Index (SSI) [17];
type of treatment; and years of therapy. We used the
Spanish-MRI (S-MRI) to establish the degree of bone
disease [18].
Diagnosis
The diagnosis of GD was established by the demonstra-
tion of low glucocerebrosidase activity in leukocytes or
fibroblasts [19]. Patients were classified as type 1, 2, or
3, according to their neurological symptoms, which
were evaluated by a neurologist. In some younger
patients, future neurological involvement cannot be
ruled out. Moreover, in some cases, neurological disease
could be due to factors other than genetic GD.
Genetic analysis
Full GBA gene sequencing was not performed in all
patients. Samples were first screened for N370S and
L444P mutations. In some patients, N370S, L444P,
D409H, G377S, N396T, 55bpdel, and N188S were the
only mutations analysed. Long-chain PCR and nested
PCR or PCR reactions using gene-specific primers were
employed to amplify the segments of the functional
GBA gene in patients with unknown mutant alleles. The
amplification products were subjected to DNA sequen-
cing to detect new mutations. In double heterozygous
patients, the phase was established by genotyping the
parents, if the material was available. To exclude the 55
bp deletion in exon 9, all patients from SGDR who were
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previously described [15]. In addition, to identify true
L444P homozygosity or rearrangements involving
L444P, two fragments of 250 and 223 bp that comprise
exon 9 and 10 respectively were sequenced in patients
from SGDR who were apparently homozygous for
L444P.
Data analysis
Descriptive statistics were used to analyse the data in
this study, according to the demographic and clinical
characteristics of GD. Proportions were calculated for
categorical variables (e.g., sex, genotype, ethnicity, and
neurological characteristics). Summary statistics (mean,
standard deviation [SD] and percentiles) were calculated
for continuous measures (e.g., age). The statistical and
epidemiological analyses were performed using Stata v.
10.0. The standardized incidence ratio was calculated
using an indirect standardization method.
Results
Of the 436 patients included in this series, 96.1% were
born in the IP or the Balearic or Canary Islands (Figure
1); 92 were from Portugal (21.1%), 327 (75.0%) were of
Spanish origin, and 17 (3.9%) were immigrants from
Cuba (n = 1), Brazil (n = 1), Ecuador (n = 1), France (n
=2 ) ,G e r m a n y( n=1 ) ,G u i n e a( n=1 ) ,I n d i a( n=1 ) ,
Morocco (n = 2), Romania (n = 2), Syria (n = 1), Turkey
(n = 1), the UK (n = 1), and Uruguay (n = 2).
Patients born in the IP were classified by diagnosis:
370 as GD type 1 (88.3%) (mean age: 40.6 ± 20.30 years,
range 0.3-87); 28 as GD type 2 (6.7%) (mean age: 0.4
years, range 0-1); and 21 as GD type 3 (5.0%) (mean
age: 5.9 years, range 2-17).
Mean age at diagnosis among all GD patients was 26.3
± 19.88 years (range 0-87); 34% of type 1 patients were
diagnosed under 18 years old (mean age 8.8 y; range:
2.5-17 y). The majority of type 1 patients (66%) were
diagnosed in adulthood (> 18 years old), mean age: 30.8
y (range 18-87 years). Figure 2 shows the distribution of
age at diagnosis in type 1 GD.
No consistent data about the time between the devel-
opment of the first symptoms and diagnosis were avail-
able for all patients, but we have recorded the time of
first therapy. The mean time between the diagnosis and
the start of therapy in type 1 patients was 18.1 years
(range 0.2-48 years).
In terms of sex, 198 (47.3%) patients were female and
203 (48.4%) male, with data unavailable in 4.3% of cases.
To date, 63 patients from the IP in this series have died
(15%). With respect to type, 7.6% of patients with type
1, 52.4% with type 3, and 100% with type 2 have died.
The cause of death for all patients with type 3 was the
progression of neurological disease. The mean age of
death for GD type 1 patients was 60.1 (range 33-78).
The most frequent causes in this cohort were liver fail-
ure, Parkinson disease, cancer and sepsis.
The total number of inhabitants in the IP was
56,032,992 (data obtained from the Spanish National
Institute of Statistics [http://www.ine.es] and the Portu-
guese National Institute of Statistics [http://www.ine.
pt]). Therefore, the prevalence (proportion of individuals
in a population suffering from GD) in the IP was 1/
149,000 inhabitants.
We identified 69 alleles and 66 mutations. The allele
frequency and type of GBA allele distributions in the IP
are presented in Additional file 1: Table S1
Figure 1 Distribution of Gaucher Disease Patients in Iberian
Peninsula and its islands. Figure 2 Type 1 Gaucher Disease. Age at diagnosis distribution.
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quencies that accounted for 75% of the total alleles
were, in order of frequency: N370S (N = 406; 48.5%),
L444P (N = 155; 18.5%), D409H (N = 28; 3.3%), G377S
(N = 25; 3.0%), and the double mutation L444P +
E326K (N = 15; 1.8%). In twenty-eight (3.3%) of the
alleles, the mutation has not yet been identified, and the
remaining alleles corresponded to private mutations (<
1.7% of total alleles). The distribution of GBA mutations
by IP region is presented in Additional file 2: Figure S1
(supplementary material).
The most frequent genotypes overall were N370S/
L444P (Ν = 117; 27.9%), followed by N370S/N370S (Ν
= 62; 14.8%). Eighty per cent of the total GD patients
(N = 335) from the IP were compound heterozygous
with one N370S mutation or were homozygous for this
mutation. The most frequent genotype in Portugal was
N370S/N370S (N = 24; 26.1%), followed by N370S/
L444P (N = 20; 21.7%). In contrast, the most frequent
genotype in Spain was N370S/L444P (N = 97; 29.7%),
and the second most common was N370S/N370S (N =
38; 11.6%). Nevertheless these differences were not sig-
nificant (p = 0.09). In each Spanish region, the most fre-
quent genotype was N370S/L444P while the second
varied (data not shown).
In type 1 GD, the most frequent genotype was N370S/
L444P (N = 117; 31.6%) followed by N370S/N370S (N =
62; 16.8%). N370S/c.84insG accounted for (N = 10)
2.7%, and other genotypes presented frequencies of less
than 2.5% (Table 1). Type 2 GD patients had a broad
spectrum of genotypes, and 24 (85.7%) were compound
heterozygous with one mutation being L444P (Table 2).
The most frequent genotypes for type 3 GD were
L444P/L444P and D409H/D409H, each accounting for
28.6% (Table 3). Surprisingly, one patient with myoclo-
nic epilepsy classified as type 3 was compound heterozy-
gous, with one mutation being N370S. Hence, the
presence of a second mutation in the N370S allele could
be suspected. However, we sequenced all exons and
exon-intron boundaries of GBA from this patient and
excluded the presence of other mutations.
Eight patients homozygous for L444P, with no neuro-
logical involvement at diagnosis were reclassified: two as
type 2 (0.5-1 years) and six as type 3 (range 4-41 years).
Several patients described in our series had interesting
phenotypes. G377S/G195W and G377S/R463C were
found to be associated with type 3 GD, as also were the
homozygous for D409H. All patients with a genotype
homozygous for D409H developed cardiovascular and
neurological signs in the second decade of life (mean
age: 14.7 years; range 10-17).
However, neither patients with the G377S/D409H
genotype nor those who were G377S homozygous devel-
oped neurological symptoms. We found two families
Table 1 GBA genotype distribution in type 1 GD
Genotype Frequency Percent
N370S/L444P 117 31.6
N370S/N370S 62 16.8
N370S/c.84insG 10 2.7
G377S/D409H 10 2.7
N370S/G202R 9 2.4
N370S/c.1263_1317del55 8 2.2
N370S/R120W 6 1.6
N370S/G195W 5 1.3
N370S/Rec all gene 5 1.3
N370S/RecNciI 5 1.3
N370S/T134P 5 1.3
N396T/N396T 5 1.3
G377S/G377S 4 1.1
N370S/G377S 4 1.1
N370S/N396T 4 1.1
N370S/R47X 4 1.1
N370S/RecTL 4 1.1
N370S/Y313H 4 1.1
N370S/F109V 3 < 1
N370S/L336P 3 < 1
N370S/[N188S;E326K] 3 < 1
N370S/P391L 3 < 1
N370S/R163X 3 < 1
N370S/R257X 3 < 1
N370S/R463C 3 < 1
N370S/[c.(-203)A > G;IVS4-2a > g] 3 < 1
N370S/c.500insT 3 < 1
N370S/[E326K;L444P] 2 < 1
N370S/G325W 2 < 1
N370S/IVS2+1 2 < 1
N370S/M123T 2 < 1
N370S/[RecNciI;c.1263_1317del55] 2 < 1
N370S/V15M 2 < 1
N370S/V191G 2 < 1
N370S/W(-4)X 2 < 1
N370S/Y412H 2 < 1
N370S/c.1439_1445del7 2 < 1
D409H/[N188S;E326K] 1 < 1
H311R/R359Q 1 < 1
L444P/G377S 1 < 1
L444P/L444P 1 < 1
N370S/G113E 1 < 1
N370S/IVS5+1 g > t 1 < 1
N370S/M123K 1 < 1
N370S/N188S 1 < 1
N370S/Q169X 1 < 1
N370S/R257Q 1 < 1
N370S/RecTL 4 1.1
N370S/Y313H 4 1.1
N370S/F109V 3 < 1
N370S/L336P 3 < 1
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Genotype Frequency Percent
[E326K;L444P]/R463H 3 10.7
L444P/G195E 3 10.7
L444P/c.1263_1317del55 3 10.7
D409H/R120W 2 7.1
[E326K;L444P]/[E326K;L444P] 2 7.1
L444P/L444P 2 7.1
L444P/R120W 2 7.1
[E326K;L444P]/G202R 1 3.6
[E326K;L444P]/W312R 1 3.6
G389E/unknown 1 3.6
[E326K;L444P]/L444P 1 3.6
L444P/G202R 1 3.6
L444P/I270P 1 3.6
L444P/RecNciI 1 3.6
L444P/S364R 1 3.6
L444P/c.203_204insC 1 3.6
N392I/L444P 1 3.6
V15M/G195W 1 3.6
D409H/R120W 2 7.1
[E326K;L444P]/[E326K;L444P] 2 7.1
L444P/L444P 2 7.1
L444P/R120W 2 7.1
[E326K;L444P]/G202R 1 3.6
[E326K;L444P]/W312R 1 3.6
G389E/unknown 1 3.6
[E326K;L444P]/L444P 1 3.6
L444P/G202R 1 3.6
L444P/I270P 1 3.6
L444P/RecNciI 1 3.6
L444P/S364R 1 3.6
L444P/c.203_204insC 1 3.6
N392I/L444P 1 3.6
V15M/G195W 1 3.6
Total 28
Table 3 GBA genotype distribution in type 3 GD
Genotype Frequency Percent
D409H/D409H 6 28.6
L444P/L444P 6 28.6
L444P/D409H 2 9.5
[E326K;N188S]/L444P 2 9.5
[E326K;L444P]/D409H 1 4.8
[E326K;L444P]/P182L 1 4.8
G377S/G195W 1 4.8
N370S/G195W 1 4.8
R463C/G377S 1 4.8
Total 21
Table 1 GBA genotype distribution in type 1 GD
(Continued)
N370S/[N188S;E326K] 3 < 1
N370S/P391L 3 < 1
N370S/R163X 3 < 1
N370S/R257X 3 < 1
N370S/R463C 3 < 1
N370S/[c.(-203)A > G;IVS4-2a > g] 3 < 1
N370S/c.500insT 3 < 1
N370S/[E326K;L444P] 2 < 1
N370S/G325W 2 < 1
N370S/IVS2+1 2 < 1
N370S/M123T 2 < 1
N370S/[RecNciI;c.1263_1317del55] 2 < 1
N370S/V15M 2 < 1
N370S/V191G 2 < 1
N370S/W(-4)X 2 < 1
N370S/Y412H 2 < 1
N370S/c.1439_1445del7 2 < 1
D409H/[N188S;E326K] 1 < 1
H311R/R359Q 1 < 1
L444P/G377S 1 < 1
L444P/L444P 1 < 1
N370S/G113E 1 < 1
N370S/IVS5+1 g > t 1 < 1
N370S/M123K 1 < 1
N370S/N188S 1 < 1
N370S/Q169X 1 < 1
N370S/R257Q 1 < 1
N370S/R285C 1 < 1
N370S/R359Q 1 < 1
N370S/R359X 1 < 1
N370S/R395C 1 < 1
N370S/Rec(int2) 1 < 1
N370S/[RecTL;c.1263_1317del55] 1 < 1
N370S/S364R 1 < 1
N370S/W(-4X) 1 < 1
N370S/W184R 1 < 1
N370S/[c.(-203)A > G;P182L] 1 < 1
N370S/[c.(-203)A > G;P391L] 1 < 1
N370S/c.1097_1098delGC 1 < 1
N370S/c.1451_452delAC 1 < 1
N370S/c.1510_1512delTCT 1 < 1
N370S/c.708delC 1 < 1
N370S/c.838delT 1 < 1
R496H/R496H 1 < 1
unknown/unknown 2 < 1
[E326K;L444P]/unknown 1 < 1
N370S/unknown 22 5.9
Total 370
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mean age of 57.1 years (range: 50-64 years) without neu-
rological manifestations. Two patients, one homozygous
for L444P (11 years old) and the other one (30 years
old) with genotype D409H/N188S;E326K, were classified
as type 1 because no neurological signs of disorder were
observed.
For the analysis of clinical data, we considered only
the 357 patients for whom we had full information at
diagnosis. The mean SSI in type 1 GD was 7.5 ± 3.59
(range 1-25); two hundred and fifty-nine patients
(72.7%) were classified as having a mild form, 91
(25.5%) moderate, and 7 (1.8%) severe, according to the
Zimran score [17].
A total of 58 (16.2%) patients were asymptomatic.
Most of this group were diagnosed by screening the
family members of an affected GD. The asymptomatic
patient genotypes were homozygous for N370S, com-
pound heterozygous with one mutation being N370S,
and patients with the D409H/G377S genotype. It is
remarkable that 62 (17.4%) patients had been splenecto-
mized and that in 40 (64.5%) of these cases the proce-
dure was performed before enzyme replacement therapy
(ERT) was available, this observation is the consequence
of adequate therapy. In the remaining 22 cases, the
spleen removal was performed in different circum-
stances before the diagnosis of GD. A total of 315
(88.4%) non-splenectomized patients at diagnosis had
spleen enlargement. Only 5 type 1 patients had docu-
mented pulmonary hypertension and all of them were
previously splenectomized.
The liver was enlarged (1.25 times the predicted nor-
mal) in 243 (68.0%) patients at diagnosis, 48 (77.4%)
splenectomized and 171 (58.1%) non-splenectomized.
Without taking into account the Erlenmeyer flask
deformity, 211 (62%) of all patients had skeletal involve-
ment; 42 (67.7%) splenectomized and 132 (44.7%) non-
splenectomized patients had bone disease (ranging from
painful crises to fractures); and orthopedic surgery had
been required in 98 (27.5%) cases.
Anemia in female patients (N = 169) (hemoglobin <
12 g/L) was present in 95 (56.2%) cases, and 107
(56.9%) men had hemoglobin levels less than 13 g/L. A
total of 198 (55.5%) GD patients at diagnosis had
thrombocytopenia (platelet counts < 100 × 10
9/L), and
29 (14.4%) had severe thrombocytopenia (platelet counts
<5 0×1 0
9/L). Leucopenia (leukocytes < 4 × 10
9/L) was
present in 106 (29.7%) patients. Ferritin levels were
increased (> 500 μg/dL) in 165 (46.1%) patients; 322
(90.2%) had hypergammaglobulinemia (> 1.5 g/dL); and
61 adult patients (> 18 years old) (17.1%) had monoclo-
nal gammopathy of undetermined significance (MGUS).
A total of nine patients had documented cancer: 3 mul-
tiple myeloma, 2 lymphoproliferative disorder, 1
malignant melanoma, 1 colon carcinoma, 1 liver carci-
noma and 1 patient with meningioma and gastric
carcinoma.
According to the available data, a total of 299 patients
(83.8%) had received some kind of therapy: 246 patients
(82.3%) had received ERT for a mean of 10.2 ± 3.8 years
(range: 1-17) and mean doses of 36 ± 12 IU/kg every 2
weeks (range: 120-10 IU/kg every two weeks). In 53
patients (17.7%), oral therapy with miglustat (100 mg, t.
i.d.) had been administered for a mean of 2.1 ± 1.9
years (range: 1-6).
Discussion
The present series appears to comprise the vast majority
of IP patients known to have had GD since 1970. To
date, few studies have described the characteristics of all
patients diagnosed with GD in a large non-Jewish popu-
lation [20,21]. This study is the first that presents GD
data from the majority of patients diagnosed in Spain
and Portugal.
Our data indicate that the prevalence of GD in the IP
was 1:149,000. This prevalence is similar to that calcu-
lated for other EU populations, with the exception of
Ashkenazi Jews [22-24]. It is likely that there are
undiagnosed patients. In this regard, it is noteworthy
that in a previous study of IP patients with GD, the
number of homozygotes for the N370S mutation calcu-
lated from the general population frequency was higher
than the number of patients diagnosed [23-25]. Also of
note is the large influx of immigrants into the IP in
recent years, which is reflected in the finding that 3.9%
of all patients were foreign. The distribution of patients
by geographical area is in line with the number of inha-
bitants, ranging from 0.1 to 1.5:10
5. An exception is the
Balearic Islands, where only one patient was found.
Given that the population of these islands is 1,100,000
inhabitants, a minimum of 7 patients should have been
identified. We do not know whether this variability in
the prevalence of GD between different regions of the
IP is due to asymptomatic patients or misdiagnosis. The
distribution by sex was practically the same, as expected,
which in part reflects the fact that the disease is autoso-
mal recessive [1].
As in other series, type 1 was the most frequent
(88.3% of total cases). Some patients diagnosed pre-
viously as type 1 were reclassified as type 3 due to the
late onset of neurological symptoms. We want to
emphasize the importance of periodically performing a
careful neurological examination of all patients, particu-
larly those who have genotypes considered at high risk
for neurological involvement [5].
The identification of GD can be complex and lengthy;
while acute or rapidly progressing cases may be identi-
fied more quickly, the disease often progresses slowly,
Giraldo et al. Orphanet Journal of Rare Diseases 2012, 7:17
http://www.ojrd.com/content/7/1/17
Page 6 of 10and signs and symptoms may be subtle and easily over-
looked. The age at diagnosis in type 1 GD in this series
was mainly adulthood (mean age 28.7 years). This obser-
vation contrasts with other lysosomal storage diseases
that are usually diagnosed in childhood. The lack of
early diagnosis of type 1 GD is probably related to
severity, as 72.7% of all patients had mild forms of the
disease according to the SSI. Mean age at diagnosis in
patients from the IP was similar to that found in
patients with the N370S/N370S genotype included in
the International Gaucher Registry (the ICGG Registry)
[26]. If we compare the age at diagnosis of patients in
the IP with the Spanish Gaucher Disease Registry data
published 10 years ago, we can see a shift toward diag-
nosis at younger ages [16]. This shift may be due to a
greater awareness of the disease in recent years and the
availability of diagnosis. On the other hand, there is not
a rigid relationship in type 1 patients between genotype
and age at diagnosis. Affected siblings with an identical
GBA genotype frequently developed different onset of
symptoms and clinical manifestations.
In relation to spleen removal, patients who had under-
gone splenectomy were more common among older GD
patients. We note that the proportion of splenectomized
patients was lower than that observed in a similar series
published 10 years ago [16]. The difference may result
from the availability of enzyme treatment therapy and is
the logical consequence of adequate therapy, which has
reduced the practice of splenectomy.
More than half of the patients had thrombocytopenia
(platelet count < 100 × 10
9/L), and 14.4% had severe
thrombocytopenia (platelet count < 50 × 10
9/L). Similar
data for platelet counts in GD patients were reported
from the ICGG Registry: 15% demonstrated severe
thrombocytopenia with platelet counts less than 60 ×
10
9/L; 45% had moderate thrombocytopenia (platelets >
60- < 120 × 10
9/L) at diagnosis. However, the percen-
tage of patients with anemia in the IP (56%) was higher
than that reported by the ICGG Registry, which showed
that 36% of registered patients were anemic at diagnosis.
This may result from the different criteria used to con-
sider a patient anemic, depending on hemoglobin levels.
We used the WHO criteria, whilst data from the ICGG
Registry were based on hemoglobin concentrations for
men and women of < 12 and < 11 g/dL, respectively
[27,28]. Most cases of anemia in GD patients are
thought to be related to increased red blood cell
destruction in the spleen [29]. Hepatomegaly was found
in 68% of patients. The effect of splenectomy on liver
enlargement was considerable, with 58.1% of patients in
the non-splenectomized cohort presenting with hepato-
megaly, compared with 77.4% in the asplenic cohort (p
< 0.01).
The association of GD with polyclonal and monoclo-
nal gammopathies has previously been reported [30,31].
A high percentage of GD patients in this series had
hypergammaglobulinemia and MGUS, as well as
increased ferritin levels. It has been postulated that pro-
gressive glucocerebroside accumulation may cause
chronic stimulation of the immune system and conse-
quent lymphoproliferation [32]. Ferritin release from
Gaucher cells has been identified as involved in reducing
T-cell function and immunoglobulin M release from B-
cells [33].
As in other series, we found that bone involvement
was one of the most disabling aspects for patients with
type 1 GD: 62% of all patients had some type of bone
involvement, including bone crises and fractures. This
condition was more frequent in asplenic patients than in
patients with spleens, suggesting that splenectomy wor-
sened bone disease. Similar results were observed in
patients included in the ICGG Registry [26]. Further-
more, splenectomized patients had larger livers and
more frequently reported a history of bone pain, bone
crises, and severe radiological evidence of bone disease
than non-splenectomized patients. A total of 27.5% of
patients needed to undergo an orthopedic procedure in
spite of the ERT. This indicates that bone disease is an
unresolved problem in a high percentage of patients.
Analysis of the mutations in GD is an interesting way
of gaining knowledge about the geographical and ethnic
origins of the disease. A total of 69 alleles and 66 differ-
ent mutations have been identified in the IP. We
included several variants in the analysis because they
produce a more severe phenotype in combination with
another mutation. This is the case of the variant E326K
associated with the L444P and N188S mutations. The
double-mutant allele [L444P;E326K] was found to
further decrease residual enzyme activity and to be asso-
ciated with a more severe phenotype than expected
f r o mt h es i n g l eL 4 4 4 Pa l l e l e .T h es a m ew a sf o u n df o r
the polymorphism c.(-203)A > G[34,35].
The most frequent mutation in individuals with GD in
the IP was N370S, followed by L444P. The two muta-
tions together accounted for 67% of total alleles. This
finding has important implications for genetic diagnosis.
Initially, the analysis can focus on these two mutations.
If both alleles are identified, GBA gene sequencing is
not necessary. However, the number of different muta-
tions in the remaining 33% of alleles identified in the
GBA gene in the IP is high, making genetic characteriza-
tion more complex. Interestingly, ten patients had
c.84insG. This insertion had been considered to occur
only in Ashkenazi Jews.
Although there is no strict relationship between geno-
type and phenotype, the fact that most patients are
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N370S, which is considered a low-severity mutation,
could be a plausible explanation for the high percentage
of patients with mild and moderate forms of the disease
(72.7% and 25.5%, respectively).
The most frequent mutation among type 1 patients
was N370S, which accounted for 54.7% of total alleles.
However, in type 3 patients, there was one compound
heterozygous individual, with one mutation being
N370S (genotype N370S/G195W). It is important to
point out that we do not know if the cause of neurologi-
cal impairment in this case was the GBA gene or
another gene, a gene-gene interaction, or a gene-envir-
onment interaction. L444P was the most frequent muta-
tion in patients with type 2, as well as among type 3
patients, where it accounted for 33.9% and 38.1% of
total alleles, respectively. It is interesting to note that
homozygosity for L444P was found in two patients clas-
sified as type 2 and in six as type 3, and homozygosity
for [E326K; L444P] occurred only in one type 2 GD
patient.
Two mutations, D409H and G377S, represented 6.3%
of total alleles. Both mutations in homozygosity or in
heterozygosity with another mutation have been asso-
ciated with a broad spectrum of GD phenotypes. This is
the case for the D409H mutation in which homozygous
patients present a rare form of type 3 GD characterized
by heart valve calcification [36]. In contrast, unlike a
report from Croatia, we did not observe heart valve dis-
ease in the four patients homozygous for G377S [37].
This finding further proves that patients with the same
genotype can have different phenotypes, which empha-
sizes the influence of other genetic and/or environmen-
tal factors.
Surprisingly, certain genotypes were not associated
with neurological involvement. This is the case of GD
patients carrying the fourth most frequent mutation,
G377S, which in homozygosity (G377S/G377S) or in
heterozygosity with the D409H mutation (G377S/
D409H) or even with the L444P mutation (G377S/
L 4 4 4 P )r e s u l t e di no n l ym i l do rm o d e r a t ef o r m so ft h e
disease, with no neurological involvement. However, this
mutation in compound heterozygosity with two mis-
sense mutations, G195W or R463C (G377S/G195W or
G377S/R463C genotypes), was found in patients who
developed neurological symptoms during childhood
(type 3 GD patients). Similar observations were reported
in patients from Brazil, who were compound heterozy-
gous with one mutation being G377S [38]. Another
interesting observation was the combination of the dou-
ble-mutant allele [E323K;N188S] with two mutations
that are considered severe: D409H and L444P. The gen-
otype L444P/[E323K;N188S] was found in patients with
GD type 2/3, and the genotype D409H/[E326K;N188S]
was present in GD type 1/3 patients. These findings
indicate that several mutations cannot be unambigu-
ously classified as mild and suggest an allele-dose effect
for them.
Before the problem of the imiglucerase shortage (June
2009 to the end of 2010), most patients were under
ERT, and only a smaller percentage were treated with
miglustat. It is important to note that the number of
patients treated with miglustat was less than the ERT
value, because the indication for treatment is specific to
individual patients.
In conclusion, we found a large heterogeneity of GBA
gene mutations among IP patients and the clinical pre-
sentation of GD patients, and little relationship between
genotype and phenotype. The prevalence of the N370S
mutation in Spanish GD patients is one of the highest
in Europe, and that of L444P is one of the lowest world-
wide. These findings contrast with observations in
closed populations in which the “founder” effect is evi-
dent. In such populations, the number of mutations giv-
ing rise to GD is small, which facilitates a rapid genetic
diagnosis. The information presented here adds to our
understanding of the clinical spectrum of GD, highlights
the genetic and phenotypic heterogeneities and empha-
sizes the need for caution in making generalizations
about GD across demographic groups.
Disclosures
Conflict of interest: none declared.
Additional material
Additional file 1: Table S1(Supplementary material GBA allele
frequencies in GD patients born in IP (Spain and Portugal).
Additional file 2: Figure S1 Allelic distribution of GBA mutations in
Iberian Peninsula and its islands.
Acknowledgements
The authors thank all the members of the Spanish Gaucher Disease Group
(SGDG) who provided clinical data and samples. The complete list of
physicians of the SGDG who have contributed is available on the website,
http://www.feeteg.org. The authors are also extremely grateful to the
patients and their families whose participation made this work possible. This
study was partially supported by the grants FIS PS09/2556, SAF2010-17589,
2009SGR-971 CIBERER, FEETEG and Fundación Ramón Areces 2010.
Author details
1Centro de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER), Zaragoza, Spain.
2Instituto de Investigación Sanitaria de Aragón
(IIS), Zaragoza, Spain.
3Spanish Gaucher Disease Foundation (FEETEG),
Zaragoza, Spain.
4Barcelona Institut de Bioquímica Clínica (Errores
Congénitos del Metabolismo), Hospital Clinic; IDIBAPS, Barcelona, Spain.
5Barcelona Departament de Genètica, Facultat de Biologia, Universitat de
Barcelona; IBUB, Barcelona, Spain.
6Portuguese Coordinating Committee for
the Treatment of Lysosomal Storage Diseases, CCTDLS (1993-2005), Institute
for Molecular and Cell Biology of Porto, Porto, Portugal.
7Departamento de
Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza,
Giraldo et al. Orphanet Journal of Rare Diseases 2012, 7:17
http://www.ojrd.com/content/7/1/17
Page 8 of 10Zaragoza, Spain.
8S° Hematología Hospital Universitario Miguel Servet, P°
Isabel La Católica, 1-3 50006 Zaragoza, Spain.
Authors’ contributions
Study conception and design: Dr. Giraldo, Dr. Pocovi, Dr Sa Miranda, Dr
Grinberg, Dr Vilageliu; Analysis and interpretation of data: Dr. Alfonso, Dr.
Irún, Dr. Gort, Dr. Chabas; Drafting the article or revising it critically for
important intellectual content: Dr. Giraldo, Dr. Pocovi, Dr Chabas, Dr
Grinberg, Dr Vilageliu.
Competing interests
The authors declare that they have no competing interests.
Received: 31 October 2011 Accepted: 19 March 2012
Published: 19 March 2012
References
1. Beutler E, Grabowski GA: Gaucher disease. In The Metabolic and Molecular
Bases of Inherited Diseases. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle
D. New York: McGraw-Hill; 2001:3635-3668.
2. Tylki-Szymanska A, Keddache M, Grabowski GA: Characterization of
neuronopathic Gaucher disease among ethnic Poles. Genet Med 2006,
8:8-15.
3. Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, Ferreira P: Gaucher
disease among Chinese patients: review on genotype/phenotype
correlation from 29 patients and identification of novel and rare alleles.
Blood Cells Mol Dis 2007, 38:287-293.
4. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E: The
human glucocerebrosidase gene and pseudogene: structure and
evolution. Genomics 1989, 4:87-96.
5. Giraldo P, Capablo JL, Alfonso P, Garcia-Rodriguez B, Latre P, Irun P, de
Cabezon AS, Pocovi M: Neurological manifestations in patients with
Gaucher disease and their relatives, it is just a coincidence? J Inherit
Metab Dis 2011, 34:781-787.
6. Grabowski GA, Horowitz M: Gaucher’s disease: molecular, genetic and
enzymological aspects. In Gaucher’s disease. Edited by: Zimran A. London:
Baillieres Clin Haematol Bailliere Tindall; 1997:635-656.
7. Beutler E, Gelbart T: Glucocerebrosidase (Gaucher disease). Hum Mutat
1996, 8:207-213.
8. Beutler E, Gelbart T, Scott CR: Hematologically important mutations:
Gaucher disease. Blood Cells Mol Dis 2005, 35:355-364.
9. Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y: Mutation prevalence
among 47 unrelated Japanese patients with Gaucher disease:
identification of four novel mutations. J Inherit Metab Dis 1997, 20:67-73.
10. Arnaiz-Villena A, Martínez-Laso J, Alonso-García J: Iberia: population
genetics, anthropology, and linguistics. Hum Biol 1999, 71:725-743.
11. Côrte-Real HB, Macaulay VA, Richards MB, Hariti G, Issad MS, Cambon-
Thomsen A, Papiha S, Bertranpetit J, Sykes BC: Genetic diversity in the
Iberian Peninsula determined from mitochondrial sequence analysis. Ann
Hum Genet 1996, 60:331-350.
12. Cormand B, Vilageliu L, Burguera JM, Balcells S, Gonzàlez-Duarte R,
Grinberg D, Chabas A: Gaucher disease in Spanish patients: analysis of
eight mutations. Hum Mutat 1995, 5:303-309.
13. Cormand B, Grinberg D, Gort L, Chabás A, Vilageliu L: Molecular analysis
and clinical findings in the Spanish Gaucher Disease population:
putative haplotype of the N370S ancestral chromosome. Hum Mutat
1998, 11:295-305.
14. Amaral O, Lacerda L, Santos R, Pinto RA, Aerts H, Sá Miranda MC: Type 1
Gaucher disease: molecular, biochemical, and clinical characterization of
patients from northern Portugal. Biochem Med Metab Biol 1993, 49:97-107.
15. Alfonso P, Aznarez S, Giralt M, Pocoví M, Giraldo P: Mutation analysis and
genotype/phenotype relationships of Gaucher disease patients in Spain.
J Hum Genet 2007, 52:391-396.
16. Giraldo P, Pocoví M, Pérez-Calvo JI, Rubio-Félix D, Giralt M: Report of the
Spanish Gaucher’s disease registry: clinical and genetic characteristics.
Haematologica 2000, 85:792-79.
17. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E:
Gaucher’s disease. Clinical, laboratory, radiologic, and genetic features of
53 patients. Medicine (Baltimore) 1992, 71:337-353.
18. Roca M, Mota J, Alfonso P, Pocoví M, Giraldo P: S-MRI score: A simple
method for assessing bone marrow involvement in Gaucher disease. Eur
J Radiol 2007, 62:132-137.
19. Raghavan SS, Topol J, Kolodny EH: Leukocyte beta-glucosidase in
homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet
1980, 32:158-173.
20. Eto Y, Ida H: Clinical and molecular characteristics of Japanese Gaucher
disease. Neurochem Res 1999, 24:207-211.
21. Sobreira E, Pires RF, Cizmarik M, Grabowski GA: Phenotypic and genotypic
heterogeneity in Gaucher disease type 1: a comparison between Brazil
and the rest of the world. Mol Genet Metab 2007, 90:81-86.
22. Cox TM, Schofield JP: Gaucher’s disease: clinical features and natural
history. Baillieres Clin Haematol 1997, 10:657-689.
23. Lacerda L, Amaral O, Pinto R, Oliveira P, Aerts J, Sá Miranda MC: Gaucher
disease: N370S glucocerebrosidase gene frequency in the Portuguese
population. Clin Genet 1994, 45:298-300.
24. Horowitz M, Pasmanik-Chor M, Borochowitz Z, Falik-Zaccai T, Heldmann K,
Carmi R, Parvari R, Beit-Or H, Goldman B, Peleg L, Levy-Lahad E, Renbaum P,
Legum S, Shomrat R, Yeger H, Benbenisti D, Navon R, Dror V, Shohat M,
Magal N, Navot N, Eyal N: Prevalence of glucocerebrosidase mutations in
the Israeli Ashkenazi Jewish Population. Hum Mutat 1998, 12:240-244.
25. Dimitriou E, Moraitou M, Troungos C, Schulpis K, Michelakakis H: Gaucher
disease: frequency of the N370S mutation in the Greek population. Clin
Genet 2010, 78:195-196.
26. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G,
Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A: The Gaucher
registry: demographics and disease characteristics of 1698 patients with
Gaucher disease. Arch Intern Med 2000, 160:2835-2843.
27. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M,
Grabowski GA, Mistry PK, Tylki-Szymańska A: Therapeutic goals in the
treatment of Gaucher disease. Semin Hematol 2004, 41(4 Suppl 5):4-14.
28. Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT,
Erikson A, Giraldo P, Goldblatt J, Hollak C, Ida H, Kaplan P, Kolodny EH,
Mistry P, Pastores GM, Pires R, Prakash-Cheng A, Rosenbloom BE, Scott CR,
Sobreira E, Tylki-Szymańska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A:
Gaucher disease type 1: revised recommendations on evaluations and
monitoring for adult patients. Semin Hematology 2004, 41(4 Suppl
5):15-22.
29. Zimran A: Survey of hematological aspects of Gaucher disease.
Hematology 2005, 10:151-156.
30. Brady K, Corash L, Bhargava V: Multiple myeloma arising from monoclonal
gammopathy of undetermined significance in a patient with Gaucher’s
disease. Arch Pathol Lab Med 1997, 121:1108-1111.
31. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA,
Rick M, Gralnick HR: Polyclonal B-cell lymphocytosis and
hypergammaglobulinemia in patients with Gaucher disease. Am J
Hematol 1988, 29:189-194.
32. Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, Pinkhas J: Gaucher’s
disease: a disease with chronic stimulation of the immune system. Arch
Pathol Lab Med 1982, 106:388-391.
33. Bassan R, Montanelli A, Barbui T: Interaction between a serum factor and
T-lymphocytes in Gaucher disease. Am J Hematol 1985, 18:381-384.
34. Chabás A, Gort L, Diaz-Font A, Montfort M, Santamaría R, Cidrás M,
Grinberg D, Vilageliu L: Perinatal lethal phenotype with generalized
ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/
P182L genotype: effect of the E326K change in neonatal and classic
forms of the disease. Blood Cells Mol Dis 2005, 35:253-258.
35. Alfonso P, Pampín S, García-Rodríguez B, Tejedor T, Domínguez C,
Rodríguez-Rey JC, Giraldo P, Pocoví M: Characterization of the c. (-203)A >
G variant in the glucocerebrosidase gene and its association with
phenotype in Gaucher disease. Clin Chim Acta 2011, 412:365-369.
36. Chabás A, Cormand B, Grinberg D, Burguera JM, Balcells S, Merino JL,
Mate I, Sobrino JA, Gonzàlez-Duarte R, Vilageliu L: Unusual expression of
Gaucher’s disease: cardiovascular calcifications in three sibs homozygous
for the D409H mutation. J Med Genet 1995, 32:740-742.
37. Perić Z, Kardum-Skelin I, Puskarić BJ, Letilović T, Vrhovac R, Jaksić B: An
unusual presentation of Gaucher’s disease: aortic valve fibrosis in a
patient homozygous for a rare G377S mutation. Coll Antropol 2010,
34:275-278.
Giraldo et al. Orphanet Journal of Rare Diseases 2012, 7:17
http://www.ojrd.com/content/7/1/17
Page 9 of 1038. Rozenberg R, Araújo FT, Fox DC, Aranda P, Nonino A, Micheletti C,
Martins AM, Cravo R, Sobreira E, Pereira LV: High frequency of mutation
G377S in Brazilian type 3 Gaucher disease patients. Braz J Med Biol Res
2006, 39:1171-1179.
doi:10.1186/1750-1172-7-17
Cite this article as: Giraldo et al.: Mapping the genetic and clinical
characteristics of Gaucher disease in the Iberian Peninsula. Orphanet
Journal of Rare Diseases 2012 7:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Giraldo et al. Orphanet Journal of Rare Diseases 2012, 7:17
http://www.ojrd.com/content/7/1/17
Page 10 of 10